1,499
Participants
Start Date
November 5, 2013
Primary Completion Date
May 22, 2024
Study Completion Date
February 3, 2025
Relatlimab
Nivolumab
BMS-986213
Relatlimab + Nivolumab
Local Institution - 0017, Lausanne
Local Institution - 0023, Vienna
Local Institution - 0024, Vienna
Local Institution - 0029, North Sydney
Local Institution - 0028, Copenhagen
Local Institution - 0020, Herlev
Local Institution - 0033, Melbourne
Local Institution - 0031, Brisbane
Local Institution - 0039, Southport
Local Institution - 0032, Nedlands
Local Institution - 0016, Zurich
Local Institution - 0005, New York
Local Institution - 0038, Marseille
Local Institution - 0047, Allentown
Local Institution - 0014, Milan
Local Institution - 0004, Baltimore
Local Institution - 0046, Málaga
Local Institution - 0006, Pamplona
Local Institution - 0026, Toulouse
Local Institution - 0058, Tampa
Local Institution - 0035, Padua
Local Institution - 0037, Nantes
Local Institution - 0007, Essen
Local Institution - 0011, Detroit
Local Institution - 0003, Chicago
Local Institution - 0048, Niles
Local Institution - 0044, St Louis
Local Institution - 0036, Pierre-Bénite
Local Institution - 0040, Heilbronn
Local Institution - 0057, Dallas
Local Institution - 0045, Houston
Local Institution - 0053, Aurora
Local Institution - 0013, Napoli
Local Institution - 0018, Villejuif
Local Institution - 0041, Würzburg
Local Institution - 0002, Portland
Local Institution - 0008, Seattle
Local Institution - 0052, Chuo-ku
Local Institution - 0054, Sunto-gun
Local Institution - 0055, Nagoya
Local Institution - 0043, La Jolla
Local Institution - 0001, Boston
Local Institution - 0051, Rochester
Local Institution - 0010, Pittsburgh
Local Institution - 0049, Toronto
Local Institution - 0050, Québec
Local Institution - 0021, Helsinki
Local Institution - 0059, Sapporo
Local Institution - 0025, Amsterdam
Local Institution - 0019, Oslo
Local Institution - 0015, Barcelona
Local Institution - 0027, London
Local Institution - 0022, London
Local Institution - 0034, Manchester
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY